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Lipopolysaccharide (LPS) from gram negative bacteria is a 
potent amphiphile which stimulates sensitive cells (e.g. 
macrophages, neutrophils) to secrete biologically active 
molecules that have protective (enhanced immune response, 
tumor cell destruction) and pathological (hypersensitivity 
reactions, toxicity) activities. Lipoteichoic acids (LTA) 
isolated from gram positive bacteria are chemically 
different but have structural features and physical 
properties similar to LPS. LTA, unlike LPS, has no reported 
toxicity. This study involved a comparison of the relative 
ability of LTA and LPS to activate arachidonic acid 
metabolism in macrophage cultures. Peritoneal macrophages 
from mice were labelled with [̂ H] arachidonic acid and 
stimulated with LTA or LPS. LPS from Salmonella dyortus or LTA 
from Streptococcusfaecalis or Staphylococcus aureus or Bacillus 
steorothermophilus activated arachidonic acid metabolism. 
Pretreatment with LTA from Streptococcus faecalis or Staphylococcus 
aureus desensitized macrophages to subsequent challenge with 
toxic LPS from Salmonella abortus. LTA from Bacillus subtilis activated 
arachidonic acid metabolism to a lesser extent, but did not 
desensitize macrophages to challenge with LPS. Cells 
desensitized to LPS and LTA responded to phorbol myristate 
acetate stimulation. This suggests that desensitization is 
an initial step in the arachidonic acid activation pathway 
occurring at some point preceding the release of 
diglyceride. These findings may be important in controlling 
endotoxic shock. Inhibition of phospholipase C, protein 
kinase C and phospholipase A2 , steps in the arachidonic acid 
release pathway, blocked arachidonic acid release in cells 
stimulated by LPS or LTA. This suggests that arachidonic 
acid release in macrophages stimulated by LPS and LTA are 
similar, at least to some extent, both involving 
phospholipase c, protein kinase C and phospholipase Aj in 
the activation process.
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INTRODUCTION
Biological response modifiers (BRM) are substances 
which enhance the immune response by causing sensitive cells 
(macrophages, neutrophils, lymphocytes) to release a variety 
of mediators. These mediators act as messengers which are 
released from one cell to activate another cell, or as 
mediators which promote phagocytosis, activate natural 
killer cells, enhance antibody production and activate cells 
involved in specific and non-specific resistance. The 
mediators include tumor necrosis factor (TNP) (44,52) the 
interleukins (22,44,52), platelet activating factor (PAF) 
(22,44), interferons (44) and eicosanoids (22,44) among 
others. This study is focused on the release of eicosanoids 
by macrophages. Eicosanoids are derivatives of arachidonic 
acid (5-c/j-, 8 -CÜ-, 11-c/j-, 14-cü- eicosatetraenoic acid) , a
C2 0 polyunsaturated fatty acid (40). Several bacterial 
structural components and products are potent biological 
response modifiers. The lipopolysaccharide (LPS) of gram- 
negative bacteria is one of the most well characterized BRM. 
LPS stimulates macrophages to release arachidonic acid which 
is metabolized to eicosanoids that have protective (e.g. 
tumor cell destruction, bacterial killing) and pathological 
(e.g. inflammation, hypersensitivity) properties. 
Lipoteichoic acids of gram-positive bacteria have a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
different chemical structure but some of the same physical 
properties of LPS. The major objective of this study was to 
compare the activities of LTA to LPS in macrophage cultures.
Lipopolysaccharide
Lipopolysaccharide (LPS, also called endotoxin) is an 
integral component of the outer membrane of gram negative 
bacteria. LPS consists of three regions having contrasting 
biological and chemical properties - 'O' specific 
polysaccharide chain, core polysaccharides, and the lipid A 
region which is linked to the core polysaccharide by means
al
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Figure l. structure of lipopolysaccharide
of 2-keto-3-deoxyoctalonic acid (KDO) (Fig. 1) (31). The
toxic activity of LPS has been shown to reside in the lipid 
A region (38,62). The majority of lipid A structures 
studied contain a p(1-6)-linked D-glucosamine disaccharide 
that carries two phosphoryl groups- one bound as an ester to 
the non-reducing glucosamine and the other to the 
glycosidic hydroxyl group of the reducing glucosamine
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Fig.2) (38). This lipid A backbone has substituted groups
(designated R1-R6 in Fig. 2). These groups include 
nitrogen containing residues, D-arabinose, phosphate (Rl,
R2, R3) and long chain acyl groups (R5 and R6 ). The R4 
group is the KDO group that links lipid A to the 
polysaccharide core (38). Evidence for the involvement of 
the lipid A in binding to macrophages came from experiments 
that showed that monoclonal antibodies against the lipid A 
moiety inhibited LPS binding to macrophages (46). Tahri- 
Jouti gt. âl (46)
have shown that 
enzymatic or 
chemical removal 
of the fatty acids 
of lipid A reduced 
binding of LPS to 
macrophages. LPS 
can bind directly 
to a receptor(s) 
or as a complex 
with a plasma
protein - lipopolysaccharide binding protein (LBP), (39).
The LPS-LBP complex binds to the CD14 receptor on the 
surface of macrophages (60). Studies using monoclonal 
antibodies to synthetic derivatives of lipid A suggested 
that more than a single LPS receptor exists on the surface
Figure 2. Structure of lipid A
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of a macrophage and that different spatial configurations of 
lipid A are recognized by different receptors (46).
LPS is responsible for many of the harmful 
manifestations seen in patients with gram negative sepsis or 
endotoxemia. Among these are pyrogenic activity, 
hypoglycemia, changes in blood clotting and blood pressure, 
and organ damage which can result in shock and even death 
(22,37). Neutrophils, platelets, vascular endothelium cells 
and macrophages appear to be the major cells involved in 
endotoxic injury (22). The interaction which initiates 
endotoxic injury appears to occur between LPS and 
macrophages, resulting in the release of cytokines and lipid 
mediators (37).
Tumor necrosis factor (TNF) and interleukin-1 (IL-l), 
released by macrophages on LPS stimulation, appear to be the 
primary mediators of endotoxic shock (22,37). Evidence that 
the macrophage is the critical cell in the host response to 
LPS comes from studies on LPS resistant mouse strain 
C3H/HeJ, and LPS sensitive mouse strain C3H/HeN (22). These 
mice are genetically identical except for the LPS 
resistance/sensitive gene. In contrast to LPS sensitive 
mice , the LPS resistant mice do not produce certain 
cytokines and show decreased prostaglandin (an eicosanoid 
derived from arachidonic acid) release in response to LPS. 
Further, the LPS resistant C3H/HeJ mice normally cannot be 
sensitized to endotoxin by galactosamine, a compound that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
markedly increases sensitivity to endotoxin in normal 
animals. if macrophages from C3H/HeN mice are transferred 
to LPS resistant C3H/HeJ mice, then they can be sensitized 
by galactosamine.
Lipoteichoic acid (LTA), like LPS, is a bacterial 
amphiphile. All LTAs, which have been characterized, 
consist of an anionic polymer with a terminal hydrophobic 
group (14,55). Most LTAs which have been characterized 
consist of a 1,3, linked polyglycerophosphate moiety in a 
phosphodiester linkage to a membrane glyceroglycolipid 
(14,15,56). The hydrophobic glyceroglycolipid is anchored 
at the outer surface of the cytoplasmic membrane, with the 
glycerophosphate chain extending into the environment. The 
glyceroglycolipid anchor of most LTAs
0-CH,
I *HC-O-OO-R 
0—CO—R
Figure 3. Structure of Lipoteichoic acid {Su^hylococcus aureus)
consists of a disaccharide unit linked to a diacylglycerol
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(dihexosyldiacylglycerols) (Fig. 3) (14,15). The
glyceroglycolipids of some LTAs have three fatty acid 
residues (triacylglycerols). This third fatty acid is 
bonded to Cg of the diacylglycerol linked saccharide and 
anchors the LTA more firmly in the membrane (14). In LTAs 
that have a third fatty acid the saccharides are linked by a 
C l -  C2 or - C4 bond, leaving the Cg of the 
diacylglycerol linked saccharide free to bind the fatty 
acid. The most common fatty acids in LTA are Ĉ g and Ĉ g 
saturated fatty acids (14). LTAs with a non-glycosylated 
lipid anchor are rare, but have been identified in a few 
bacterial species. The length of the polyglycerophosphate 
chain varies from 16 to 40 glycerophosphate units, depending 
on the bacterial species (14,15,56). The number of group 
substitutions in the glycerol residues also varies from one 
bacterial species to another. Based on chain substitution, 
bacterial LTA can be divided into four groups: group A lacks 
substituents, group B carries only D-alanine substituents, 
group C carries only glycosyl substituents, and group D 
carries both these substituents. No other substituents have 
been identified (56).
The role of LTA in pathogenesis of gram positive 
bacteria has received relatively little attention. The 
inflammatory components implicated in gram positive 
bacteremia are cell wall components (peptidoglycan, teichoic 
acids, and protein A), toxins (a-toxin, enterotoxin), and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
enzymes (proteinase, coagulase). No role for LTA in gram- 
positive bacteremia has been reported. Recently, Brade ^  
al (6 ) reported that a 28 kD protein of normal mouse serum 
bound both LTA and LPS. This 28 kd serum protein bound to 
the lipid A-proximal inner core region of LPS. Initial 
investigations have shown that the sugar acid KDO is 
required for binding of this protein. Brade et al. (6 ) 
suggest that an unidentified moiety, similar to KDO in 
conformation, may exist in LTA. It is evident from this 
that there are humoral factors and cellular factors that 
recognize LPS and LTA. Several research groups (47,61) have 
reported that LTA has some immunological and biological 
properties in common with LPS. For example, Tarsi-Tsuk and 
Levy (47) recently reported that LTA from Streptococcus faecalis
stimulates the respiratory burst in blood monocytes.
Macrophage Activation
Activated macrophages play a critical role in host 
defense against tumors and microbes, in the inflammatory 
response, in homeostasis and in disease such as 
atherogenesis, and carcinogenesis (Fig. 4) (21). Adams (1 )
has pointed out that macrophage activation is not restricted 
to the development of anti-microbial or anti-neoplastic 
function, but can be broadly defined as an increased 
competence to perform a variety of functions associated with 
host defense. The functional ability of macrophages is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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strictly regulated by extracellular signals. These 
extracellular signals can either enhance or diminish the 
ability of macrophages to carry out a certain function (2 1 ). 
The precise mechanisms of macrophage activation are diverse, 
but there is always the involvement of two fundamental 
steps: (1 ) initial recognition of the extracellular stimuli; 
and (2 ) subsequent physiological changes that result in one 
or more of the following; secretion of potent mediators 
(cytokines), changes in surface properties, and metabolic 
changes (e.g. respiratory burst).
Measure of Macrophage activation
Activated macrophages show a variety of metabolic 
activities (1) (Fig. 4). The metabolic activities that are 
most commonly used to measure macrophage activation are 
described.
1) Respiratory burst: Activated cells show an enhanced
oxidative metabolism called the respiratory burst. This 
results from the activation of the NADPH oxidase system 
which catalyses the synthesis of metabolites (e.g. 
superoxide anion, hydrogen peroxide, hydroxyl radical etc.), 
which have potent anti- microbial activities. This 
respiratory burst can be measured by cytochrome c reduction 
(47) .
2) Secretion of proteins and glycoprotein mediators:
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Activated macrophages secrete several different kinds of 
proteins and glycoproteins that have enzymatic or 
immunostimulating activity. These include plasminogen 
activator, lysosomal hydrolases, cytotoxic proteinases, and 
the interferons (44).
3) Release of tumor necrosis factor (TNF) and interleukin-1 
(IL-l): TNF and IL-l, which appear to be the primary 
mediators of endotoxic shock (35) are synthesized de novo 
and are released as a consequence of microbial stimulation, 
in particular LPS, or tissue injury (23,37,44).
4) Display of altered surface properties: A selective
remodelling of the membrane, as a consequence of activation, 
results in expression of several receptors that enhance 
macrophage function. Some of the components expressed by 
activated macrophages are receptors for complement (CR3), 
receptor for the Fc portion of immunoglobulin (FcR), and the 
a2 ~*macroglobulin receptor (44) .
5) Release of arachidonic acid metabolites (eicosanoids):
Arachidonic acid is released from membrane phospholipids by 
the action of phospholipase C and/or phospholipase Aj. It 
is then metabolized to other eicosanoids either by the 
cyclooxygenase pathway (prostaglandins, thromboxanes) or the 
lipoxygenase pathway (leukotrienes, hydroxyeicosatetraenoic 
acid and lipoxins) (35,40). The products of arachidonic 
acid metabolism mediate a number of reactions that have 
various biological effects.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 5. Structure of Arachidonic Acid
In this study, cell activation was assayed by the 
release of eicosanoids from cells labeled with [̂ H] 
arachidonic acid. Arachidonic acid (Fig, 5) is an essential 
fatty acid which is incorporated into membrane phospholipids 
(40). There is little, if any, free (non esterified) 
arachidonic acid in unstimulated cells. In an analysis of 
the eicosanoid products released from mouse macrophage 
cultures stimulated with LPS from 5. abortus equi, Aderem and
Cohn (2) recovered over 97% of the total released label as 
prostaglandins and leukotrienes, and less than 2 % as free 
arachidonic acid.
Several studies have suggested that the release of 
other mediators may be dependent on some step(s) or products 
of arachidonic acid metabolism. For example, Tarsi-Tsuk et 
al (47) reported that inhibition of arachidonic acid
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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metabolism caused a decrease in the respiratory burst (17). 
Likewise, release of TNF was suppressed by the inhibition of 
arachidonic acid metabolism (35).
Mechanism of Macrophage Activation
The mechanism of signal transduction in phagocytic 
cells (macrophages and neutrophils) has been investigated in 
some detail with the synthetic peptide N-formyl-methionyl- 
leucy1-phenylalanine (f-Met-Leu-Phe) (43) and to a lesser 
extent with LPS. The most well characterized steps in 
macrophage activation are summarized below.
Receptors and 6-protein: G-proteins are a group of plasma
membrane components that serve a signal transducing function 
between a variety of receptors and intracellular components 
(21,50). Common characteristics of G-proteins include 
GTPase activity and a heterotrimeric apy structure (50). A 
model of the receptor mediated stimulation of 
phosphotidlyinositol (PIPg) specific phospholipase c (PLC) 
via G-protein is depicted in Fig. 6 A (42,44). Receptor- 
ligand binding stimulates GTP to substitute for GDP on the 
a-subunit of G-protein which promotes dissociation of the a 
subunit from the P and y subunits (44,50). This forms the 
activated G-protein - GTP complex. The G-protein - GTP 
complex causes the activation of a phosphatidylinositol-4,5- 
bisphosphate (PIPg) specific phospholipase C (PLC) (44,50).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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The activated PLC (i.e. G-protein - GTP - PLC - calcium 
complex) then hydrolyses PiPj to diacylglycerol (DAG) and 
inositol triphosphate (IP3 ) (42,42,50). Both, DAG and IP3
derivatives are mediators.
A protein of 60-70 KD, which is coupled to a G- 
protein, has been identified as the receptor for f-Met-Leu- 
Phe peptides by covalent cross-linking technic[ues (44). 
Subsequent to the addition of agonist, the number of cell 
surface receptors is initially decreased by endocytosis, and 
then increased, which suggests that the receptor is recycled 
(44), A receptor which binds LPS, referred to as CD14, has 
been identified on the surface of macrophages and monocytes 
(60). CD14 is a 55 KD glycoprotein that is attached to the 
membrane via a phosphatidylinositol anchor (60). CD14 
appears to be a receptor for a complex of LPS and a 60 KD 
serum glycoprotein, called lipopolysaccharide binding 
protein (LBP) (60) . LBP forms high affinity complexes with 
smooth as well as rough LPS. LBP will also bind to the 
bacterial cell surface. Wright et al (60) exposed whole 
blood to various concentrations of LPS in the presence or 
absence of monoclonal antibodies to CD14. LPS at low 
concentrations induced TNF production. This response was 
eliminated by blocking antibody to CD14, 3C10 or 60b. It 
was suggested that CD14 facilitates binding of LPS-LBP 
complexes to the cell surface in such a way that other 
proteins or components of the cell surface were activated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(60). This suggestion was supported by the fact that 
increasing the concentration of LPS tenfold caused TNF 
synthesis in the absence of CD14 or LBP (60). It appeared 
that binding of LPS was different than binding mechanisms of 
other stimuli such as lymphokines and hormones. Wright et 
al (60) also suggested that LPS formed a soluble complex 
with LBP which then bound to the membrane receptor, 
following which, G-proteins were involved in transduction of 
LPS signal (12,60). If G-protein function was inhibited by 
pertussis toxin, which inhibits G-protein signalling 
components by ribosylating the active site, LPS induced 
responses in macrophages were prevented (4,12,50).
PLB
PLA,
PLA,
R. C
PLC
PL A, = Pnosofioiipass A . 
PLA, .  PMospnoip9s« A ,  
PLB •  Pnocpnoiipas* 8  
PLC = Pnospnouoase C 
Pl O = Pnoapnoicase O
PLD
Phospholipase c: Activation
of PLC appears to be a 
common mechanism for various 
receptor-1 igand 
interactions, including f- 
met-leu-phe, platelet 
activating factor (PAF), and 
complement component C5a
Figure 8. Site of hydrolysis of (^l)• Specifically, PLC 
phospholipases mediates a phosphodiester
cleavage of phosphoinositol-4,5-bisphosphate to form 
inositol phosphate and diacylglycerol. Stimulation of PLC 
by the receptor-1igand-G-protein sequence is primarily due
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to a decrease in the Câ "̂  requirement of PLC, such that the 
enzyme is active at ambient Câ'*' concentrations (51) .
Diacylglyoeride and Protein Kinase C: The diacylglycerol
(DAG) formed from action of PLC is a source for arachidonic 
acid by the action of a diglyceride lipase. DAG is also an 
important mediator which can activate protein Icinase C.
,
CH. OCR CH. OCR
R’COCH gpC T —>  HOCOCH +  R”O  I  O  I
CH . OH CH . OH
sn*1.2'Oiaoytalyoprol MonoacylQiyoarol r ” — Araohidonio add
Protein kinase C plays a central role in leukocyte 
activation and may be involved in differentiation of 
monocytes to macrophages (59). Studies using phorbol esters 
(33), which are analogues of DAG for activation of protein 
kinase C, have shown that activation of protein kinase C 
involves its redistribution from the cytosolic to the
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membrane fraction (36,59). In unstimulated
polymorphonuclear leukocytes (PMN) 90% of the protein kinase 
C activity is in the cytosolic fraction; however, on 
stimulation by f-met-leu-phe, protein kinase C is 
translocated to the plasma membrane (33,3 6 ). Inhibition of 
protein kinase C translocation to the plasma membrane by 
pharmacological agents inhibits the respiratory burst (59). 
Cell permeable analogues of DAG that activate protein kinase 
C stimulate different activation pathways (11,16). For 
example, the DAG analogue sn-1 ,2-didecanoylglycerol 
stimulated degranulation without increasing superoxide 
production by PMNs. In contrast, another DAG analogue, sn- 
1 ,2 -dioctanoyIglycerol stimulated both degranulation and 
superoxide production in PMNs. Coussens et ai., (10) 
suggested that protein kinase C is present in isozyme forms 
or is compartmentalized. These observations also suggest 
that different activation pathways (e.g. respiratory burst, 
secretion of metabolites) are regulated differently (1 0 ).
The source of DAG is not necessarily PI. Snyderman and 
Uhing (44) found that DAG production stimulated by receptor- 
ligand interaction occurred from two sources - PI and PC. 
These workers suggested that DAG production occurred in two 
phases: first from PI hydrolysis, which was accompanied by 
an increase in calcium concentration in the cytosol, and 
second, from the hydrolysis of phosphotidylcholine by 
calcium stimulated PLC.
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Phosphollpase Ag: Protein kinase C has several effects
including phosphorylation of several proteins that modulate 
gene expression and activation of phospholipase A2 (PLAj) 
(2 1 ). PLAg cleaves arachidonic acid from membrane 
phosphotidylcholine (PC) , which is the second pathway of 
arachidonic acid release.
CH. OCR CH. OCR
'  C o J î H  V  H O C O C H  +O  I  9  o  I  oC H .  O R ^ ^ ^ C T  C H .  O R ^ ; ^ C F
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3«pt>ot(ctytot-io<in« 1 - •oyl-elyoeroptioephooiiollne R"— ArmohMomIc #da
Researchers are divided on whether arachidonic acid 
released in response to a specific receptor-ligand 
interaction occurs by a PLC dependent pathway or PIA2 or 
both. It is likely that different stimuli elicit 
arachidonic acid release from different sources. Walsh 
âi./(53) have reported that zymosan and ionophores stimulate 
arachidonic acid release in neutrophils by PLA2 .
Experiments performed by Walsh et ai.,(53) demonstrated that 
neutrophils stimulated with zymosan and ionophores showed no 
increase in levels of labeled DAG or monoacyIglycerol, which 
are products formed by the action of phospholipase C on 
phosphatidylinositol (see Fig. 6 ). Sporn et ai., (45) have 
shown that the biologically active oxidant H2O2 , and the
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particulate stimuli zymosan, activated arachidonic acid 
metabolism in alveolar macrophages by different pathways.
In their study, the protein kinase C (PKC) inhibitor, 
staurosporine, inhibited zymosan stimulated arachidonic acid 
metabolism, but was relatively ineffective in inhibiting 
HjOj stimulated arachidonic acid metabolism. Thus, zymosan 
activates PKC, which then activates phospholipase A2 
mediated arachidonic acid metabolism. In contrast, HgOg 
activates arachidonic acid metabolism by at least two 
pathways, a PKC dependent pathway involving PLA2 activity 
and a second pathway that is PKC independent. Sporn et al.. 
(45) suggested two possible PKC independent mechanisms of 
activating arachidonic acid metabolism - release of 
arachidonic acid from diacylglyceride (DAG) by the action of 
glyceride lipase (i.e. by activating phospholipase C) and by 
inhibition of arachidonic acid reacylation. Arachidonic 
acid turnover rates in macrophages are high (30) and 
inhibition of its reacylation would result in accumulation 
of free arachidonic acid which would activate arachidonic 
acid metabolism. Kroner et sJL* # (29) have demonstrated that
sulfydryl reactive chemicals (e.g. para- 
chloromercuribenzoate) stimulated arachidonic acid and 
prostaglandin release by a PIA2 independent mechanism by 
inhibiting reacylation of arachidonic acid into 
phospholipids.
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Role of Calcium: Calcium is necessary in receptor mediated
leukocyte activation. Inositol-l,4#5-trisphosphate (IP3 ), 
formed by the action of phospholipase C on phosphatidyl 
inositol, has been shown to cause the release of calcium 
from intracellular stores (7,37). The calcium ionophore 
(e.g. A23187) will stimulate leukocytes in the presence of 
sufficient extracellular calcium. Verghese êt ai., (50) 
have shown that the sequence of 1 igand-receptor interaction, 
G-protein activation, phosphatidylinositol metabolism, and 
calcium influx are necessary events in activation of 
monocytes. They showed that inhibition of G-proteins with 
Bordetella pertussis toxin inhibited subsequent steps of
phosphatidylinositol metabolism, calcium mobilization and 
cell activation. Tarsi-Tsuk âi*r (47) have shown that 
stimulation of the respiratory burst in monocytes with 5.
faecalis lipoteichoic acid (LTA) required an increase in
cytosolic calcium levels. Treatment of these monocytes with 
calcium ionophore, however, caused a negligible respiratory 
burst, suggesting that an increase in cytosolic calcium 
levels is not the sole requirement for an LTA mediated 
respiratory burst. According to Aderem and Cohn (2), 
stimuli that mobilize large amounts of intracellular 
calcium, such as zymosan and immune complexes (particulate 
stimuli), cause secretion of both cyclooxygenase and 
lipoxygenase products, whereas stimuli that mobilize small 
amounts of calcium, such as PMA (soluble stimuli) promote
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secretion of only the cyclooxygenase products. They 
demonstrated that PMA, in the presence of calcium ionophore 
A23187, would activate the 5-lipoxygenase pathway and that 
this resulted in secretion of both products. According to 
Aderem and Cohn (2), small amounts of calcium, such as those 
generated by PMA alone, are sufficient to stimulate 
phospholipases but not 5-lipoxygenase, i.e. phospholipases 
have a higher affinity for calcium than 5-lipoxygenase.
Their suggestions are consistent with the Km values of 
purified phospholipase C and 5-lipoxygenase.
In contrast to the above observations, Klein et aJL. ,
(28) reported that an influx of extracellular calcium into 
the cytosol is not a necessary step in activation of 
neutrophils by LPS. However, intracellular calcium 
processes are essential for activation of neutrophils by 
LPS. They measured expression of C3bi (a receptor for 
complement that is expressed in activated neutrophils) in 
LPS stimulated neutrophils and found no increase in 
expression of C3bi. Inhibition of the influx of 
extracellular calcium into the cytosol by EGTA and calcium- 
channel blockers had no effect on expression of C3bi. Quin- 
2 , an agent that binds calcium and interferes with 
intracellular calcium metabolism, partially inhibited C3bi 
expression. This inhibition was overcome by A23187, which, 
by allowing influx of extracellular calcium, reversed the 
effects of quin- 2  (28).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
23
Desensitization of Macrophages
Upon repeated administration of small amounts of LPS, 
the response of the host to LPS challenge decreases. This 
phenomenon is called tolerance or desensitization (18,32). 
Although the mechanism of LPS induced tolerance is unknown, 
tolerance in other systems has been shown to involve 
modification of membrane receptors (14). Haas et. ai., (20)
reported that mice which were desensitized to LPS were able 
to activate nuclear factor kfi (NF-kB), a DNA binding protein 
required for TNF gene transcription, nevertheless, 
transcription of the TNF gene did not occur. Henricson et. 
al. . (21) observed that pretreatment with either LPS at 
subiethal doses or monophosphory1 lipid A (MPL), a 
relatively nontoxic LPS derivative, could induce a state of 
tolerance in mice when subsequently challenged with lethal 
doses of LPS. LPS (25 ^g) and MPL (200 nq) induced 
comparable levels of colony stimulating factor (CSF), a 
cytokine that stimulates proliferation of bone marrow 
derived precursor cells, however, the levels of interferon 
(IFN), TNF, and interleukin- 6  (IL-6 ) were approximately 10- 
fold lower in MPL pretreated mice. They suggested that the 
diminished toxicity of MPL may be due to significantly lower 
levels of toxic products such as TNF, IFN, and IL- 6  
released, yet enough is produced to permit a low dose
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synergy required for induction of tolerance (35). Further, 
they suggested that chemical differences between LPS and MPL 
may cause conformational differences in the lipid A moiety 
such that MPL binds with a lower affinity to the LPS 
signalling receptor, or that the confirmation of MPL allowed 
it to interact with an alternative lipid A binding protein.
Coffee et ai (9) have suggested that altered G-protein 
responses could be involved in tolerance to endotoxin. 
Endotoxin tolerant and control macrophage cultures were 
treated with the stable non-hydrolyzable GTP analogue GTP[y- 
S] which stimulates arachidonic acid release. There was 
significantly decreased thromboxane release in response to 
Gt p [y-S] in endotoxin tolerant macrophages. Arachidonic 
acid depletion, loss of phospholipase activity, or loss of 
cyclooxygenase activity were shown to be unlikely reasons 
for the decrease because calcium ionophore A23187 caused 
more thromboxane release by the endotoxin tolerant cells 
than the control cells. Since tolerance to endotoxic shock 
is also accompanied by tolerance to other forms of shock, 
including epinephrine shock, hemorrhagic shock, and 
myocardial ischemia (9), it is possible that decreased or 
altered G-protein function may cause resistance to other 
stimuli by preventing signal transduction beyond the 
receptor. This cross tolerance cannot be transferred 
passively, indicating that it is cellular and not humoral 
(9) •
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Inhibitors of the pathway of arachidonic acid release and 
arachidonic acid metabolism
The pathological effects mediated by the products of 
arachidonic acid metabolism can be inhibited by agents that 
interfere with the activation of arachidonic acid release or 
by agents that block metabolism of arachidonic acid to 
biologically active prostaglandins, thromboxanes, 
leukotrienes and lipoxins. Commonly used drugs such as 
aspirin (17) and indomethacin (17,41) prevent prostaglandin 
formation by inhibiting cyclooxygenase activity, whereas 
drugs such as benoxaprofen (17) inhibit the lipoxygenase 
activity preventing leukotriene formation. Inhibitors that 
prevent arachidonic acid release, exert their effect by 
blocking one or more steps in the activation pathway. Some 
of the commonly used inhibitory agents of arachidonic acid 
release are listed below.
a) Neomycin: inhibits phosphoinositide metabolism, and 
therefore phospholipase C mediated arachidonic acid 
release (8 );
b) Hydrocortisone: inhibits phospholipase C (17);
c) Quinacrine: inhibits phospholipase Aj activity (13);
d) Staurosporine: inhibits protein kinase C (54);
e) H-7: inhibitor of protein kinase C (25);
f) Pertussis toxin: inhibits function of G-proteins and 
therefore transduction of signal beyond receptor
(4) .
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OBJECTIVE
The major objective of this study was to compare the 
effect of lipoteichoic acid (LTA) from gram-positive 
bacteria to that of lipopolysaccharide (LPS) from gram- 
negative bacteria on arachidonic acid metabolism in 
macrophage cultures. Native LPS from E. coli and related
organisms is highly toxic and has potent immunostimulatory 
activity. The development of effective biological response 
modifiers from LPS has focused on the efforts to reduce the 
toxicity while retaining the immunostimulatory properties of 
the LPS molecule. Lipoteichoic acid from several gram- 
positive bacteria has been reported to be non-toxic. If LTA 
has immunostimulatory activity then, it may have potential 
as a therapeutic agent.
Specific aims:
1. To determine the relative ability of different LTA 
preparations to activate arachidonic acid metabolism in 
mouse peritoneal macrophages. Several studies have 
suggested a correlation between the immunostimulatory and 
toxic properties of different LPS preparations and their 
relative potency as measured by eicosanoid release.
2. To determine the effect of lipoteichoic acid treatment
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on the ability of macrophage to respond to LPS. The toxemia 
which occurs in gram-negative infections results, in part at 
least, from products produced by activated macrophages. A 
substance which specifically desensitizes macrophages to LPS 
could be an important agent for controlling these 
infections.
3. To determine the pathway of macrophage activation. 
Specific inhibitors of different steps in eicosanoid 
metabolism will be used in an attempt to characterize the 
pathway of arachidonic acid release and subsequent 
metabolism.
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MATERIALS AND METHODS
Collection of resident macrophages from mouse peritoneum.
Mice were killed with CO2 then 10 ml of cold Iscove's 
or RPMI medium (Sigma Chemicals, St.Louis, MO), pH 7.1, 
without serum, was injected into the peritoneal cavity. The 
fluid in the peritoneum was aspirated carefully so that no 
bleeding occurred. About 7 - 8 ml of medium was retrieved 
per mouse. The cells were sedimented in a Beckman model J- 
6 8  centrifuge at 250 x g for 10 minutes at 4*C, then 
resuspended in 1 0  ml medium with 1 0 % fetal bovine serum 
(FES, Hyclone laboratories, Logan, UT).
Cells were counted using a hemacytometer and the cell 
density adjusted to 2 - 2.5 x 10® cells/ml. The cell 
suspension was added (0.5 ml/well) to a 24 well flat-bottom 
plate. Cells were incubated at 37»C, in a chamber with 5% 
CO2 for 2 hours to allow macrophages to adhere. Non­
adherent cells were then removed and fresh medium added.
Treatment of macrophages with LTA and LPS prior to 
challenge.
Macrophage cultures were treated prior to the labeling 
and challenge step during the second hour of the adherence 
period (pretreatment). Cells were treated with 10 jug/ml of 
LTA or LPS as required. Control cells received medium
28
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without LTA/LPS. After one hour treatment at 37®C the cells 
were washed and labeled in fresh medium.
Labeling of cells with arachidonic acid.
Adherent cells (macrophages) were washed once with 
medium, then 1 ml (or 0.5 ml) of medium containing [̂ H] 
arachidonic acid (0.5 ^Ci/well or 0.25 /ütCi/well) in medium 
with 10% FBS was added to each well. Cells were incubated 
overnight at 37®C in a chamber with 5% COg.
Challenge of macrophages with LTA or LPS.
At the end of the overnight incubation the excess label 
was removed and the cells washed three times with medium. 
Cells were then challenged with 0.5 ml LPS from S.abortus
(Ribi Immunochem, Hamilton, MT) in medium with serum at 
concentrations of 0 .1 , 1 , 1 0 , 1 0 0 , and 1 0 0 0  ng/ml or with 
0.5 mis LTA txom S.faecalis, S.aureus or B.subtilis (Sigma Chemicals,
St.Louis, MO) in medium with serum at concentrations of 1,
10, 100, 1000, and 10000 ng/ml. In some experiments the 
cells were challenged in medium without serum, as indicated. 
Cells were incubated at 37®C for 2 hours in a chamber with 
5% CO2 . At the end of the incubation period the medium from 
each well was collected and centrifuged in an Eppendorf 5414 
table top centrifuge to exclude any cells. Released [%] 
arachidonic acid was determined in 2 0 0  /il duplicate samples 
collected in scintillation vials with 4 mis of flour
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(Ecolume, ICN Biochemicals, Irvine, CA) and read in a 
Beckman LS 7500 scintillation counter. For determination of 
total counts, adhered cells were lysed with 0.5 ml of 0.5% 
triton X-lOO to release label, then the wells were scraped, 
and radioactivity read in duplicate samples as described 
above.
Treatment with agents that modulate the arachidonic acid 
pathway;
Phorbol myristic acetate (PMA) and calcium ionophore 
A23187 were used as activators of the arachidonic acid 
pathway. PMA and calcium ionophore A23187 were used to 
challenge cells, as described above for LTA and LPS, at 
concentrations of 1 , 1 0 , 1 0 0 , 1 0 0 0 , and 1 0 0 0 0  ng/ml in media 
with or without serum, as indicated. Indomethacin (41), 
neomycin (8 ), quinacrine (13), and staurosporine (54) were 
used as inhibitors of specific steps of the arachidonic acid 
activation pathway. Inhibitors were used either in the 
pretreatment, labeling, or challenge period, as indicated. 
When used in the challenge step, the inhibitor was added 30 
minutes prior to addition of LPS or LTA followed by a 2 hour 
incubation period. The concentrations of the inhibitors 
used were: indomethacin 10"®, quinacrine 10 mM and 1 mM, 
staurosporine 1 #g/ml and 1 0  ftg/ml, and neomycin 6 . 2  mg/ml 
and 1 mg/ml.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
RESULTS 
Effect of LTA and LPS on [̂ H] arachidonic acid uptake
One of the goals of this study was to determine the 
effect of LTA on the subsequent sensitivity of macrophage 
cultures to LPS. It was important, therefore, to show that 
LTA did not block the uptake of (̂ H) arachidonic acid during 
the labeling period. Cells were treated with 1 0  Mg/ml o f S.
faecalis LTA in RPMI medium for one hour prior to the addition
of label. Samples were taken from duplicate wells at 
intervals for 24 hours. Label not taken up by cells was 
assayed by measuring label in medium (data not shown).
Label taken up by cells was measured by aspirating the 
remaining medium, then washing the adhered cells three times 
to remove any remaining label. The cells were then lysed by 
adding 0.5 ml triton X-100 to each well. The wells were 
scraped, and label taken up by cells counted. It is clear 
from the results shown in Fig. 9 that LTA treatment actually 
increased (%) arachidonic acid uptake. After 10 hrs, LTA 
treated cells showed an uptake of 26 % of the total label 
added, whereas untreated cells took up 17 % of the total 
label. The results suggested that activation results in 
increased turnover of membrane arachidonic acid.
31
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Fig. 9: Effect of LTA on arachidonic acid uptake.
Resident peritoneal macrophages from mice were pretested 
with lOMg/ml of S. faecalis LTA in RPMI medium (+) or with RPMI 
medium alone (o) for one hour. The cells were then 
incubated with [̂ H] arachidonic acid (0,25 mCi/well). At 
intervals the cells were washed to remove label in medium, 
lysed with 0.5 ml/well of 0.5% triton X-100, the wells 
scraped, and label taken up by cells measured. Values are 
the mean of four samples.
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Eff#ot Of serum on eicosanoid release.
The influence of serum during the challenge period was 
studied by challenging cells with LPS in RPMI with and 
without 10% fetal bovine serum (FBS). Cells challenged in 
RPMI with serum released more label than cells challenged in 
RPMI alone (Fig. IDA and lOB).
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Fig* 10: Effect of serum during the challenge period.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid, washed, and challenged with S. abortus 
LPS in RPMI with or without serum (10% FBS). Data shown as 
CPM released (A) and % CPM released of control (B).
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LTA activated arachidonic acid metabolism
House peritoneal macrophages were labeled with [̂ H] 
arachidonic acid and challenged with LTA from the Gram- 
positive bacteria S. aureus (Fig. 1 2 ), S. faecalis (Fig. 12), B.
subtilis (Fig, 14A) , and B. stearothermophilus (Fig. 14B) . The
response to LTA was compared to the response to LPS from 
Salmonella abortus (a smooth strain) (Fig. 13). LPS from S.
abortus initiated eicosanoid release and showed a maximum
release at lower concentrations than LTA. Nevertheless, all 
of the LTA preparations activated eicosanoid release in the 
macrophage cultures. The total amount of eicosanoid 
released was about the same for LPS and S. aureus and S. faecalis
LTA (Fig. 13). B. subtilis UTK stimulated arachidonic acid 
release, but the amount released was much less than the 
other LTA preparations (Fig. 14A). LTA from B.
stearothermophilus stimulated release of about three times as
much arachidonic acid as LTA from S. faecalis o r  S. aureus. This
LTA must be further purified before it can be compared to 
the other preparations.
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Fig. 11: LTA from S. aureus and S ,yüeco&y activated arachidonic
acid matabolism in mous# peritoneal macrophages.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid, washed, and challenged with LTA from 
S. aureus or S. faecalis.
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Fig. 12: Release of arachidonic acid by LTA and LPS wascomparable.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid, washed, and challenged with S. abortus 
LPS or 5. faecalis LTA.
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Fig* 13: Effect of LTA from Bacittus subtilus and Bacillus
stearotherm opfülus on arachidonic acid release.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid, washed, and challenged with LTA from 
B. subtilus (A) o r B. stearothermophilus (B) .
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LTA desensitized macrophages to S. abortus LPS challenge
Macrophage cultures were pretreated for one hour with 
1 0  Mg/ral LTA from S. faecalis, S. aureus, B. subtilis or B.
stearothermophilus. Cells were then labeled with [^H]arachidonic
acid overnight, then washed and challenged with LPS from S.
abortus. LTA from S. faecalis and S. aureus desensitized macrophage
cultures to challenge with LPS from 5. abortus (Fig. 15 and
16) as was evident from a marked decrease in [3H] 
arachidonic acid released. LTA from B. subtilis did not
desensitize macrophages to LPS challenge (Fig. 17). When B.
stearothermophilus was used to pretreat cells under the same
conditions as above, the desensitization was complete (Fig. 
18). As stated above, this was a crude preparation of B.
stearothermophilus LTA and the results are c[uestionable.
Desensitization was not specific for LTA treatment or LPS 
challenge - cells treated with S. abortus LPS and subsequently
challenged with the same LPS were desensitized (Fig. 19) and 
cells treated with S. faecalis LTA and subsequently challenge
with the same LTA were also desensitized (Fig. 20).
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Fig. 14: S. fa e ca lis LTA deaensitized nacrophages to S.abortus 
LPS challenge.
Resident peritoneal macrophages from mice were pretreated 
with either 10 /itg/ml of S. faecalis LTA in Iscove's medium or 
with Iscove's medium alone (no pretreat). The cells were 
then incubated with [̂ H] arachidonic acid overnight, washed, 
and challenged with S.abortus LPS.
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Fig. 15: S.auremJ/SK desensitized macrophages to S. abortus hVB
challenge.
Resident peritoneal macrophages from mice were pretreated 
with either 10 fxg/ml  of 5, aureus LTA in Iscove's medium or 
with Iscove's medium alone (no pretreat). The cells were 
then incubated with [%] arachidonic acid overnight, washed, 
and challenged with S. abortus LPS.
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Fig. 16: B. su b tilis LTA did not dosonsitizo mncrophagos to S.
abortus LP8 chnllonge.
Resident peritoneal macrophages from mice were treated with 
either 10 f*g/ml of B. subtilis UFA in Iscove's medium or with 
Iscove*s medium alone (no pretreat). The cells were then 
incubated with [%] arachidonic acid overnight, washed, and 
challenged with S. abortus LPS.
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Fig. 17: B, aeowthermophilus LTA desensitized macrophages to S.
abortus LPS challenge.
Resident peritoneal macrophages from mice were treated with 
either 1 0  A:g/ml of B. steorothermophilus "LTK in Iscove's medium or 
with Iscove's medium alone (no LTA treatment). The cells 
were then incubated with [̂ H] arachidonic acid overnight, 
washed, and challenged with S. abortus LPS.
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Fig. 18: S, abortus LPS desensitized mecrophages to S. abortus
LPS challenge.
Resident peritoneal macrophages from mice were treated with 
either 10 ftg/ml of S. abortus LPS in Iscove's medium or with 
Iscove's medium alone (no LPS treatment). The cells were 
then incubated with [̂ H] arachidonic acid overnight, washed, 
and challenged with S. abortus LPS.
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Fig. 19: S.faecaUs LTA desensitized macrophages to S. faecalis
LTA challenge.
Resident peritoneal macrophages from mice were treated with 
either 10 ftg/ml of S, faecalis LTA in Iscove's medium or with 
Iscove's medium alone (no LTA treatment). The cells were 
then incubated with [̂ H] arachidonic acid overnight, washed, 
and challenged with S. faecalis
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Effect of LTA treatment of macrophage cultures on subsequent 
challenge with PMA and the calcium ionophore A23187
To understand the nature of desensitization by LTA 
treatment, macrophage cultures were treated with LTA from S.
faecalis then challenged with phorbol myristic acetate (PMA) ,
a stimulus that bypasses receptor mediated activation of 
cells. Cells treated with LTA were not desensitized to PMA 
challenge (Fig. 21). When calcium ionophore A23187, an 
agent that causes an influx of calcium into the cytosol, was 
used to challenge LTA treated cells, no desensitization 
occurred (Fig. 22).
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Fig. 20: 5. faecalis LTA did not desensitize macrophages to
phorbol myristate acetate (PMA) challenge.
Resident peritoneal macrophages from mice were treated with 
either 1 0  /ig/ml of S. faecalis UTK in Iscove's medium or with 
Iscove's medium alone (no LTA treatment). The cells were 
then incubated with [̂ H] arachidonic acid overnight, washed, 
and challenged with PMA.
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Fig. 21: S. faecalis LTA did not desensitise macrophages to
calcium ionophore A23187 challenge.
Resident peritoneal macrophages from mice were treated with 
either 1 0  ^g/ml of S. faeccdis TJtK in Iscove's medium or with 
Iscove's medium alone (no LTA treatment). The cells were 
then incubated with [%] arachidonic acid overnight, washed, 
and challenged with A23187.
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Effect of LTA concentration on desensitization
Fig. 23 shows the relative ineffectiveness of S.faecaUs
LTA concentrations of 10 and 100 ng/ml in desensitizing 
cells to subsequent LPS challenge. Whereas LTA 
concentrations of 1 0 0 0  and 1 0 , 0 0 0  ng/ml were equally 
effective in desensitizing cells to LPS challenge.
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Fig. 22: Effect of LTA concentrations on desensitization.
Resident peritoneal macrophages from mice were pretreated 
with either lOng/ml, lOOng/ml, lOOOng/ml, or 10,OOOng/ml 5. 
faecalis LTA in Iscove's medium for one hour. The cells were 
then incubated with [̂ H] arachidonic acid overnight, washed 
and challenged with 10 nq/val S. abortus LPS.
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Effect of time period between pretreat and challenge
To determine the period of time for which macrophage 
cultures remain desensitized after LTA treatment cells were 
treated with 10 ^g/ml of LTA, labeled, washed three times to 
remove any remaining label and subsequently challenged with 
5. abortus LPS at various intervals over a period of 72 hours.
Fig. 24 shows that cells challenged with LPS at 4 hours were 
not desensitized. At 22 hours cells were desensitized and 
then gradually became more responsive to LPS challenge at 42 
and 72 hours.
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Fig. 23: Effect of time period between LTA treatment andstibsequent LPS challenge.
Resident peritoneal macrophages from mice were treated with 
10 ^g/ml of 5. faecalis LTA in Iscove ' s medium or with 
Iscove's medium alone (no LTA treatment). The cells were 
then incubated with [̂ H] arachidonic acid. At various 
intervals» over a period of 72 hours » the cells were washed 
to remove label» and challenged with 1 0  fig/ml S. abortus LPS.
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Effect of Neomycin on LPS and LTA stimulation of macrophage 
cultures
There is evidence for both phospholipase C dependant 
and phospholipase C independent pathways of arachidonic acid 
mobilization. The role of phospholipase C in LTA activation 
of arachidonic acid metabolism was evaluated by treating 
cells with neomycin, which inhibits phospholipase C. Cells 
were allowed to adhere, labeled with [̂ H]arachidonic acid 
overnight, washed and treated with 6.2 mg/ml neomycin for 3 0 
min. The cells were then challenged with LPS. Both, LPS 
(Fig. 25) and LTA (Fig. 26) stimulated cells, showed a 
significant decrease in arachidonic acid release as compared 
to controls. Lower concentrations of neomycin were 
ineffective in inhibiting arachidonic acid release (data not 
shown).
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Fig. 24: Neomycin with LPS challenge.
Resident peritoneal macrophages from mice were labeled with 
[^H] arachidonic acid overnight, washed, and challenged with 
S. abonus LPS with or without Neomycin.
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Fig. 25: Neomycin with LTA challenge.
Resident peritoneal macrophages from mice were labeled with 
arachidonic acid overnight, washed, and challenged with 
S.faecaUs LTA with or without Neomycin.
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Effect of quinacrine on LTA and LPS stimulation of 
macrophage cultures
Quinacrine is an inhibitor of phospholipase Ag. Cells 
were allowed to adhere, labeled, washed, and then treated 
with 10 mM or 1 mM quinacrine. Thirty minutes after the 
addition of quinacrine the cells were challenged with LPS or 
LTA. Quinacrine did not inhibit arachidonic acid release at 
1 mM (Fig. 27A and Fig. 28A). At a ten-fold higher 
concentration (10 mM), however, quinacrine inhibited 
arachidonic acid release (Figs. 27B and 28B). At lower 
concentrations of quinacrine (1 mM), cells released label 
without LPS stimulation (Fig. 27A). This suggests that 
quinacrine might stimulate arachidonic acid below inhibitory 
concentrations. Also, quinacrine at 1 mM appeared to 
sensitize cells to subsequent challenge with normally non­
activating concentrations of LPS and LTA (Fig. 27A and 28A).
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Fig. 26: Quinacrine with LPS challenge.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid overnight, washed, and challenged with 
5. abortus LPS with or without 10“^M quinacrine (A) or 10“^M 
quinacrine (B) .
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Fig. 27: Quinacrine with LTA challenge.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid overnight, washed, and challenged with 
S, faecalis LTA with or without 1 0 "^M quinacrine (A) or 1 0 "^M 
quinacrine (B) .
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Effect of staurosporine on LPS and LTA stimulation of 
macrophage cultures
The role of protein kinase C in activating arachidonic 
acid release in macrophage was studied using staurosporine, 
an inhibitor of protein kinase C. Cells were cultured, 
labeled, and washed as described above. Staurosporine at 
concentrations of 1 n g /m l and 1 0  ^g/ml was added to the 
cells 30 min before challenge. Staurosporine at 1 /lig/ml did 
not inhibit arachichidonic acid release in LPS or LTA 
stimulated cells (Figs. 29A and 30A). At 10 ^g/ml, however, 
staurosporine was an effective inhibitor of arachidonic acid 
release in both LPS and LTA challenged cells (Figs. 29B and 
30B) .
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Fig. 28: 8 taurosporin# with LPS challange.
Resident peritoneal macrophages from mice were labeled with 
[^H] arachidonic acid overnight, washed, and challenged with 
S. abonus LPS with or without staurosporine at 10^ ng/ml (A) 
or 10^ ng/ml (B).
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Fig. 29: stmurosporin* with LTA challenge.
Resident peritoneal macrophages from mice were labeled with 
[̂ H] arachidonic acid overnight, washed, and challenged with 
5. faecalis LTA with or without staurosporine at 10^ ng/ml (A) 
or 10^ ng/ml (B).
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Effect of Zndomethacin on arachidonic acid release
Indomethacin is an inhibitor of cyclooxygenase. 
Prostaglandin E2 , a product of the cycloxygenase pathway, 
has been implicated in down-regulating the effects of LPS on 
macrophage. If the accumulation of PGEg contributes to 
desensitiztion then indomethacin should influence the 
response. Cells were allowed to adhere to wells, washed, 
labeled with [^H]arachidonic acid overnight with or without 
10-6 M indomethacin, washed again, and challenged with LPS. 
Cells treated with indomethacin during the labeling period 
released twice the amount of [̂ H] arachidonic acid in 
unstimulated cells (control wells with no LPS challenge).
The effect of indomethacin on desensitization was studied by 
preatreating cells with 10 f ig /m l LTA in the presence or 
absence of lO""® M indomethacin. The cells were then washed, 
labeled overnight, and challenged with LPS. Indomethacin 
(10“® M) had no effect on pretreatment (Fig. 32B). To 
determine the effect on LTA and LPS stimulation of 
macrophages, indomethacin was added 30 minutes before 
addition of LPS or LTA Figs. 31 and 32C show a basal 
increase in arachidonic acid release (wells without LPS or 
LTA) by indomethacin treated cells compared to cells without 
indomethacin. On LPS or LTA stimulation, indomethacin 
treated cell show little increase in arachidonic acid 
release as compared to cells without indomethacin.
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Fig. 30: Indomethacin with LTA challenge
Resident peritoneal macrophages from mice were labeled with 
[%] arachidonic acid overnight, washed, and challenged with 
S.faecaUs LTA with or without indomethacin (10"®M) .
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DISCUSSION
LTA activates arachidonic acid release in macrophages
LTA triggered arachidonic acid release in mouse peritoneal 
macrophages (Fig. 11). The amount of arachidonic acid 
released was comparable to that released by macrophages 
activated by stimulation with toxic LPS from S, a b o r tu s .  
Recently, Tarsi-Tsuk e^ al. (47) reported that LTA 
stimulated the respiratory burst in human blood monocytes. 
The immunological implications of the interaction of LTA 
with cells involved in the immune response is not clearly 
understood. LTA is localized at the outer surface of the 
cell membrane of gram-positive bacteria and is often 
released from the cell surface (14). It is likely, 
therefore, that it would interact with host immune cells.
The finding that LTA can stimulate arachidonic acid release 
in mouse peritoneal macrophages is especially interesting 
considering the reports that LTA is much less toxic than 
LPS. LTA induces some of the same biological and 
immunological responses which are induced by LPS (Table 1) 
but it has not been implicated in any destructive 
pathological infection.
It is not known if the metabolic events which result in 
the pyrogenic or toxic activities of LPS are the same or 
different than the metabolic events which contribute to the
65
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immunostimulatory (protective) activities of LPS. The 
preparation of a chemically modified LPS with 
immunostimulatory
Table 1. Comparision of some of the properties of LPS and 
LTA (adapted from ref. 57)
Property LPS LTA
Pyrogenicity + -
Lethal toxicity + -
Immunogenicity + -
Mitogenicity + —
Eukaryotic membrane binding + -
Hypersensitivity + -
activity but greatly reduced toxicity (49) suggests, to some 
extent at least, that these activities can be separated. 
Chemically, LTA is different from LPS, but it shares common 
physical properties with LPS. Both LPS and LTA are 
amphiphiles with a hydrophobic glycolipid moiety and a 
hydrophilic end. The lipid A region of LPS is responsible 
for most of the biological properties (31) . Removal of a 
phosphate group from Lipid A (i.e. formation of
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monophosphoryl lipid A (MPL)) results in marked reduction in 
pyrogenicity and toxicity (49). Also, removal of normal 
fatty acids or substitution of the normal fatty acids in 
lipid A (e.g., substitution of myristic acid with palmitic 
acid) results in decreased toxicity (49). The hydrophobic 
component of LTA is less complex than lipid A of LPS (57). 
wicken and Knox (57) have pointed out that LTA is closer in 
structure to eukaryotic membrane glycolipids than lipid A 
and have suggested that this may be the reason it is less 
toxic.
As shown in Figs. 11 and 13 there were differences in 
the relative potencies of different LTA preparations. S.
faecalis and 5. aureus LTA were comparable to LPS, whereas, B.
subtilis LTA was less potent. Our initial assumption was that
the differences in potency between B. subtilis and S. aureus and S.
faecalis might be due to differences in the chemical structure
of the lipoteichoic acids (Fig. 32). The LTA preparations 
of S. aureus and S. faecalis are similar in glycerol/phosphate
and a 1 anine/phosphate content. LTA of B. subtilis differs in
having a lower glycerol/phosphate and alanine/phosphate 
content. On the other hand, the glycolipid moiety of B.
subtilis and  S.aureus is similar, whereas that of S. faecalis is 
different (14,26,56). Table 2 summarizes the differences in 
the three LTA preparations.
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Table 2. (data obtained from Sigma Chemical Co. and ref. 14)
LTA gly/phos ala/phos Glycolipid
5. faecalis 0 , 8 0.13 Glc(al-2)Glc(al-3)acyl2
1 5. aureus 0 . 8 0 . 1 Glc(Pl-6 )Glc(Pl-3 )acyl2
1 B. subtilis 0 . 6 0.05 Glc(Pl-6)Glc(pl-3)acyl,
A fourth LTA pre]paration tested was from B. stearothermophilus.
This was a partially purified preparation, therefore, the 
results must be interpreted cautiously. Figure 14 
demonstrates that B. stearothermophilus LTA stimulated
macrophages to release three to four times more arachidonic 
acid than LTA preparations from S. faecalis o r  S. aureus. The LTA
of B. stearothermophilus is devoid of sugar residues in its
hydrophobic region (Card, unpublished data). The 
alanine/phosphate and glycerol/phosphate contents have not 
been determined. It was anticipated Z h a t B. stearothennophilus
LTA would be less potent because it lacked carbohydrate 
residues in the lipid region. In analogy with LPS, for 
which lipid A is the minimal structure that possesses most 
of the biological properties of LPS (31,62), it was expected 
that the biologically active part in LTA would be the 
hydrophobic glycolipid region, possibly for attachment to 
an, as yet, unidentified receptor on the surface of 
macrophages. The greater amount of arachidonic acid 
released by B. stearothermophilus LTA could have resulted from
contamination with other cell wall material such as
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MÎ Ĉ OX
M.C
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peptidogtycan or protein. B. stearothermophilus LTAwas prepared in our 
laboratory, and only partially purified.
8 » faecalis and S.aureus LTA desensitise macrophage to LPS 
challenge.
Treatment with LTA from 5. faecalis and S. aureus
desensitized macrophage cultures to subsequent response to 
LPS challenge (Figs. 14 and 15). This desensitization was 
not the result of less [̂ H] arachidonic acid uptake during 
the labeling period. Macrophage cultures treated with LTA 
took up more label than those which were not treated (Fig.
9) . This suggests that there was an increase in the 
turnover of arachidonic acid in these stimulated cells, 
resulting in an increase in both release and uptake.
The possibility of desensitizing the macrophage 
response, which results in the deleterious effects of 
endotoxin (and other inflammatory stimuli such as TNF, 
bacterial exotoxins, etc.) is of importance, considering the 
many destructive pathophysiological effects that are 
inflicted as a consequence of macrophage-endotoxin 
interaction (35). Endotoxic shock is one of the most 
serious consequences of hospital-acquired infections (62).
In recent years strategies to treat endotoxic shock have 
focused on the development of pharmacological agents that 
inhibit the formation of potent mediators (22,62). The 
successful strategies for treating endotoxic shock suggest
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that the eicosanoid products of arachidonic acid are 
important mediators in this condition (5,62). Steroidal 
(5,62) and non-steroidal (17) pharmacological agents have 
been used to control the harmful effects mediated by 
endotoxin. Steroidal inhibitors (e.g. glucocorticoids) act 
by binding to a specific receptor on the cell and initiating 
synthesis of proteins (e.g. macrocortin and lipomodulin) 
that inhibit phospholipase activity, thus preventing 
arachidonic acid release (5). Non-steroidal anti­
inflammatory agents interfere with arachidonic acid 
metabolism (17). For example, aspirin and indomethacin 
inhibit cyclooxygenase (17). Both steroidal and non­
steroidal agents, inhibit the formation of lipid mediators 
and other potent cytokines such as tumor necrosis factor 
(TNF) and platelet activating factor (PAF).
Desensitization of responding cells by pretreatment 
with biological response modifiers (BRM) such as 
lipoteichoic acid, polynucleotide complexes (34), muramyl 
peptides (12) sublethal doses of native endotoxin (19), and 
derivatives of lipid A (49) may be an effective method of 
controlling the harmful effects mediated by LPS. MPL, which 
is the most promising, has greatly reduced toxic properties 
of LPS, but retains the properties of being a potent 
adjuvant (49). Our finding that LTA desensitized 
macrophages to LPS challenge is important in view of the 
fact that LTA, like MPL, is reported to be non-pyrogenic,
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relatively non-toxic, and a potent immunogen.
Lipoteichoic acid from B. subtilis, did not desensitize 
macrophage cultures to LPS challenge (Fig. 16). B. subtilis LTA 
is chemically different from S. aureus and S. faecalis LTA in its
alanine/phosphate and glycerol/phosphate content. It is 
possible that desensitization requires a certain specificity 
and stringency in structure that B. subtilis V IA  lacks. It
should be noted that B. subtilis LTA, besides being ineffective
in desensitizing macrophage cultures, was also relatively 
ineffective in stimulating arachidonic acid release.
As shown in Fig. 18 desensitization was not specific 
for pretreatment with LTA. Cells treated with LPS were 
desensitized to subsequent LPS challenge, and cells treated 
with LTA were unresponsive to subsequent LTA challenge (Fig. 
19) .
In an attempt to understand the nature of the 
desensitization process and the cell components involved, 
cells were treated with the non-receptor mediated cell 
agonist phorbol myristic acetate (PMA) and the calcium 
ionophore A23187. Cells pretreated with LTA from S. faecalis
were not desensitized to PMA challenge (Fig. 20). PMA, an 
analog of diacylglycerol, permeates the cell membrane and 
activates protein kinase C, resulting in arachidonic acid 
release via phospholipase A2 (Fig. 33) (59,44). Since
pretreatment with LTA did not effect PMA action, it is
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Figure 33. Arachidonic acid release mediated by non­receptor mediated stimuli - phorbol myristic acetate (PMA) and calcium ionophore A23187, and receptor mediated stimuli - LPS and LTA
likely that the desensitization step occurred at a point 
before diacylglyceride release. As shown in Fig. 21  
pretreatment with LTA did not desensitize cells to calcium 
ionophore A23187 challenge. Thus, either desensitization 
did not affect the calcium dependent steps or calcium influx 
into the cytosol can overcome the desensitization. Recent 
reports have suggested that down-régulâtion of protein 
kinase activity may play a role in desensitization (45).
It was reported by Sporn et al. (45) that cells incubated in 
the presence of PMA for 18 hours had reduced protein kinase 
C levels, which resulted in a diminished response to stimuli 
(45) . The relative effectiveness of LTA for desensitization 
may be related to the relative potency in stimulating 
eicosanoid release. LTA from B. subtilis stimulated arachidonic
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acid release moderately, and was ineffective in 
desensitizing macrophage cultures to LPS challenge. All 
other LTA preparations that were tested stimulated 
arachidonic acid release to a greater degree and were 
effective in desensitizing macrophage cultures to LPS 
challenge. Other factors that might play a role in 
desensitization include modulation of receptors such that 
the second stimulus binds with a lower affinity (24), 
saturation of available sites (7); or stearic hindrance 
caused in the microenvironment of the receptor resulting in 
incomplete signal transduction. Desensitization by some 
treatments is against a wide range of stimulants which have 
different receptors (27). This suggests that 
desensitization may involve many receptors or may involve a 
step(s) subsequent to receptor-stimuli interaction that is 
common to many stimuli. Intronna &t al« * (27) suggested
that desensitization may be controlled at the 
transcriptional level. They reported that stimulation of 
cells with LPS resulted in an increase in expression of c-fos
mRNA (c-fos mRNA codes for a group of “early” proteins that 
are induced by LPS) , The levels of c-fos mRNA increased
rapidly on LPS stimulation and then decreased. During a 
period of 2 - 3  hours following treatment, during which c-fos 
mRNA remained at low levels, cells were desensitized and 
subsequent challenge with LPS did not induce higher c-fos  
mRNA levels. Full sensitivity to LPS was restored 20 hours
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later, when levels of c~fos mRNA were elevated to normal
levels. Data presented in this study showed that 
macrophages remain desensitized to LPS at least 20 hours 
after pretreatment (Fig.24). It is possible that different 
physiological branches of the activation process are 
desensitized at different times and for different lengths of 
time.
The Pathway of Araehldonio Acid Release By LTA and LPS
The rationale behind using inhibitors in this study was 
to detect differences in the mode of arachidonic acid 
release by LPS and LTA. In recent years much research has 
focused on the specific steps involved in the activation 
processes of cells stimulated by bacterial stimuli (LPS, 
peptidoglycan, exotoxins) and physiological stimuli 
(hormones, interferons, eicosanoids etc.) (1,21). It is 
known that different stimuli activate macrophages via 
different molecular mechanisms (1,21). For example, 
according to Aderem ai., (3), the calcium ionophore 
A23187 activates macrophages by a pathway that does not 
involve activation of protein kinase C, whereas PMA 
activates macrophages by a protein kinase C dependent 
pathway.
The phospholipase C inhibitor, neomycin inhibited 
arachidonic acid release in cells stimulated by both LPS 
and LTA (Fig. 24 and 25) . Neomycin binds to
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Figure 34. Pathway of arachidonic acid release showing steps at which the inhibitors acts.
phosphatidylinositol-4,5-bisphosphate (PIPg) preventing 
hydrolysis by phospholipase C (8 ). Thus, neomycin prevents 
formation of diacylglyceride (DAG) which is a source of 
arachidonic acid by the action of diacylglyceride lipase. 
DAG also activates protein kinase C (PKC), which in turn 
activates phospholipase Ag (PLA2 ) to release arachidonic 
acid from phosphotidyIcho1ine (PC). Inhibition of PI 
hydrolysis by neomycin also prevents formation of inositol- 
1,4,5 -trisphosphate (IP3), which acts as a second messenger 
in mobilizing intracellular calcium stores. According to 
the model shown in Fig. 34, inhibition of the PLC pathway
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would prevent arachidonic acid release from DAG by 
diglyceride lipase and prevent the activation of PLAg which 
acts on phosphotodylcholine (PC) to release arachidonic 
acid.
As shown in Figs. 26 and 2 1 , when the PLAj inhibitor 
quinacrine (47,48), was used there was inhibition of 
arachidonic acid release with 10"^ M quinacrine, but 10“  ̂M 
quinacrine appeared to prime macrophages for arachidonic 
acid release by LPS and LTA. Concentrations of quinacrine 
lower than 10"^ M had a priming effect (data not shown) .
The high basal release of arachidonic acid in the control 
wells (wells with quinacrine but no LPS challenge) indicated 
that quinacrine, at concentrations below inhibitory levels, 
stimulated arachidonic acid release from macrophages, but 
was inhibitory at higher concentrations. Other research 
groups (47) have used considerably lower concentrations of 
quinacrine (10“® M) to inhibit arachidonic acid release and 
the respiratory burst in human blood monocytes.
Data obtained with neomycin and quinacrine suggested 
that inhibition of either PLAj or PLC significantly 
inhibited arachidonic acid release. As shown in Fig. 34, 
inhibition of PLC would inhibit PLAg mediated arachidonic 
acid release since PLC generates DAG which is required for 
activation of PKC, which then activates PLA2 . However, PLA2 
could be activated by a PLC independent G-protein pathway. 
This G-protein mediated activation of PLA2 could release
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arachidonic acid from PC and/or phosphotidylethanolamine 
(PE) (3 0). Specific inhibition of PLAg should not block PLC 
mediated arachidonic acid release from DAG. Thus, if LTA 
and/or LPS stimulate release of arachidonic acid by a PLC 
dependent pathway, then quinacrine should not inhibit 
arachidonic acid release by LPS and/or LTA. Recent reports 
suggested that the action of quinacrine may not be specific 
(48) . Tauber and Simons (48) have suggested that q[uinacrine 
may inhibit all phosphollpases by binding to phospholipids 
and changing membrane potential which disturbs membrane 
architecture (48,55). Quinacrine may, therefore, inhibit 
glyceride lipase, which converts DAG to arachidonic acid and 
monoacylglycerol, in addition to inhibiting PLAg activity. 
This would prevent arachidonic acid release by either a PLC 
dependent pathway (from DAG) or a PLA2 pathway (from PC).
Staurosporine was used to determine the role of protein 
kinase c in LTA and LPS stimulation of arachidonic acid 
release. Staurosporine at 10 n q / m l inhibited arachidonic 
acid release from macrophages challenged with LPS or LTA. 
Cells stimulated with LPS or LTA in the presence of 1 Mg/ml 
staurosporine were not inhibited, releasing arachidonic acid 
equal in amount (or more) to cells challenged with LPS or 
LTA without staurosporine. Therefore, lower concentrations 
of staurosporine, like quinacrine, enhanced LPS and LTA 
mediated arachidonic acid release. This is in keeping with 
the observations of Watanabe &t al..(54) that staurosporine
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had dual effects: it released arachidonic acid at low 
concentrations and inhibited arachidonic acid release at 
higher concentrations. Stimuli have been reported as being 
PKC dependent or PKC independent in releasing arachidonic 
acid . For example PMA and the calcium ionophore A23187 are 
PKC dependent, whereas HgOg and hormonal stimuli are PKC 
independent (45). LTA and LPS mediated arachidonic acid 
release appeared to be PKC dependent. This suggests that 
PLAg hydrolysis of PC is a major source of arachidonic acid 
release from LPS and LTA stimulated cells.
Indomethacin, which is an inhibitor of 
cyclooxygenase, prevents formation of prostaglandins and 
thromboxanes (41). One of the prostaglandins, prostaglandin 
E2 (PGE2 ), down-regulates the activated state of the cell 
(35). According to Wightman and Dallob (58) prostaglandins 
are synthesized endogenously and accumulate during the 
period the macrophages are cultured. The addition of 
indomethacin during the overnight labeling period (about 18 
hours) resulted in a significantly higher total amount of 
arachidonic acid released when cells were subsequently 
challenged with LPS (Fig. 31A) . The addition of 
indomethacin during the LTA pretreatment step had no effect 
on desensitization (Fig. 3IB). This suggests that PGE2 does 
not play a role in the desensitization process.
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Summary
The release of ^H-arachidonic acid from the lipid pool 
of peritoneal macrophages activated by treatment with 
lipoteichoic acid from Streptococcus faecalis and
Staphylococcus aureus was similar to that observed with 
macrophages treated with toxic 1 ipopolysaccharide from 
Salmonella abortus. Macrophage cultures treated with Bacillus 
steorothermophilus LTA stimulated ^H-arachidonic acid
release to a significantly higher extent, more than any 
other LTA or LPS preparation.
Pretreatment of macrophages with lipoteichoic acid 
from Streptococcus faecalis and Staphylococcus aureus desensitized
peritoneal macrophages to challenge with toxic 
1 ipopo ly sacchar ide from Salmonella abortus.
Lipoteichoic acid from Bacillus subtilis activated
arachidonic acid metabolism to some extent but did not 
desensitize macrophages.
Peritoneal macrophages, desensitized to 
lipopolysaccharide and lipoteichoic acid challenge, 
responded to phorbol myristate acid.
Inhibitors that blocked arachidonic acid release in 
macrophage cultures stimulated by LPS also blocked 
arachidonic acid release in macrophage cultures 
stimulated by LTA.
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Future Directions
The relationship between the chemical nature of potent 
agonists, the cellular events they induce in cells of the 
immune response, and the resulting biological response they 
trigger is not clear. LPS and LTA may stimulate different 
branches of the arachidonic acid activation pathway, 
resulting in differences in the types and amounts of 
prostaglandins and leukotrienes produced. A qualitative and 
quantitative study of the prostaglandins and leukotrienes 
produced by HPLC, enzyme immunoassays, or radioimmunoassays 
may explain differences in the cell response and the 
subsequent biological effect.
The nature of the desensitized state observed in 
macrophages treated with LTA and subsequently challenged 
with LPS appears to be different from that caused by 
pharmacological agents that inhibit arachidonic acid 
metabolism (e.g. non-steroidal agents) or those that inhibit 
protein synthesis (e.g. steroidal agents) and needs to be 
addressed.
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